5 IPO Pricing Press Releases 2027: What Each Led With
By Kyle Porter, Executive Vice President & Managing Director.
Updated November 16, 2026

Five 2026 IPO pricing releases compared with their SEC filings: what each led with, lead managers, ticker placement and proceeds language, plus an IR checklist.
An IPO pricing press release leads with the size, the price per share and the word upsized, then states the exchange, ticker and expected closing. In five 2026 releases reviewed against SEC filings, all used the same headline pattern, but lead underwriters, proceeds figures and ownership details differed. This guide compares what each led with and what the prospectus added.
Updated: November 9, 2026
Contents
What does an IPO pricing press release usually contain?
A pricing release is short, formulaic and issued the evening the deal prices. The five releases below share the same building blocks, in roughly this order:
-
A headline announcing the pricing of an upsized initial public offering.
-
A first paragraph with the company description, the number of shares, the share class and the price per share.
-
Offering mechanics: whether the shares are primary or secondary, and the underwriters' 30-day option for additional shares.
-
The exchange, the ticker symbol, the expected first trading day and the expected closing date.
-
The lead underwriters or book-running managers.
-
A line on the registration statement becoming effective and where to obtain the prospectus.
-
The standard notice that the release is not an offer to sell.
-
An about section, forward-looking language and contacts.
Companies planning a listing can pair this anatomy with Virgo's guides to pre-IPO communications planning and IPO quiet period rules.
Which five IPO pricing releases are compared here?
The table summarizes each release as read on the company's or wire service's page. Dates are the release dateline dates.
CompanyRelease dateShares and priceExchange and tickerLead managers named
INNIOJun 3, 202690,000,000 shares at $27.00, all secondaryNasdaq Global Select Market, INIOGoldman Sachs, J.P. Morgan, Morgan Stanley WhiteHawk MineralsJun 8, 20267,700,000 Class A shares at $26.00NYSE, WHKRaymond James, Stifel, J.P. Morgan Odyssey TherapeuticsMay 7, 202615,500,000 shares at $18.00, plus a concurrent private placementNasdaq Capital Market, ODTXJ.P. Morgan, TD Cowen, Cantor Seaport TherapeuticsApr 30, 202614,160,000 shares at $18.00Nasdaq Global Select Market, SPTXGoldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, Stifel Braveheart BioAug 5, 202621,250,000 shares at $18.00Nasdaq Global Market, BRVEGoldman Sachs, Jefferies, TD Cowen, Stifel, Cantor
What did each of the five IPO pricing press releases lead with?
1. INNIO: size, upsize, then no proceeds
INNIO's INNIO pricing release opens with 90,000,000 common shares at $27.00 and states in the next sentence that the offering is a 15,000,000 share upsize from 75,000,000. By the end of the first paragraph it says the offering is entirely secondary and that the company receives no proceeds. It names Goldman Sachs, J.P. Morgan and Morgan Stanley as joint lead book-running managers, gives Nasdaq Global Select Market, ticker INIO and a June 4 start date, and flags a June 5 expected close. The INNIO 424B4 on EDGAR matches the share count and price.
What it shows: a secondary offering leading with the proceeds fact early so no one assumes otherwise.
2. WhiteHawk Minerals: terms first, name change inside the release
The WhiteHawk pricing release leads with 7,700,000 Class A shares at $26.00, a 775,000 share upsize from 6,925,000. It states the NYSE listing under WHK on June 9, a June 10 expected close, and that the company will change its name to WhiteHawk Minerals Corp. at closing. The release does not state gross proceeds. The WhiteHawk 424B4 on EDGAR shows a total of $200,200,000 at the public offering price.
What it shows: a release that stays on the deal terms while the prospectus carries the full story, covered in the next section.
3. Odyssey Therapeutics: one proceeds number for two transactions
Odyssey's pricing release on GlobeNewswire leads with 15,500,000 shares at $18.00 and a 2,325,000 share option. Its second paragraph announces a concurrent private placement of 1,388,889 shares to an affiliate of TPG Life Sciences Innovations at the same price. The release then gives one combined gross proceeds figure of about $304 million for the offering and the placement, and says the placement is conditioned on the IPO closing but not the reverse. Shares were expected on the Nasdaq Capital Market under ODTX on May 8. A later Odyssey 10-Q on EDGAR reports the underwriters bought 600,000 option shares and IPO net proceeds of $265.4 million on 16,100,000 shares.
What it shows: a combined headline number that is useful only because the release explains how the two deals relate.
4. Seaport Therapeutics: the top of the range, and a ticker in line one
Seaport's pricing release on its site puts the Nasdaq ticker in its first sentence, then gives 14,160,000 shares at $18.00, described as the top of the target range. It states gross proceeds of $254.9 million, that all shares are offered by the company, and a 2,124,000 share option. Five managers are named: Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel. The Seaport 424B4 on EDGAR shows $254,880,000 in total at $18.00 per share.
What it shows: the only release of the five that characterized the price against its range.
5. Braveheart Bio: proceeds stated with the option excluded
Braveheart's pricing release on GlobeNewswire opens with the Nasdaq ticker, then 21,250,000 shares at $18.00, trading on August 6 and closing on August 7. It states gross proceeds of $382.5 million and says that figure excludes any exercise of the 3,187,500 share option. Five managers are named, and the contacts line lists both an investor relations firm and a media firm. The Braveheart 424B4 on EDGAR shows $382,500,000 at $18.00 with a $1.26 per share discount.
What it shows: a clean proceeds statement that says exactly what it includes and excludes.
How did the releases differ from their SEC filings?
Pricing releases are built for speed, and the prospectus carries the detail. The table lists items we found in the filings that the releases did not mention.
CompanyWhat the release saidWhat the filing added
INNIOIssuer called INNIO Group; sole selling shareholder unnamedIssuer named INNIO N.V.; selling shareholder named as AI Alpine (Luxembourg) S.a r.l., which keeps 660,000,000 shares, about 88% of voting power WhiteHawk MineralsShares, price, listing, name change$200,200,000 total; cornerstone investors indicated interest of up to $74 million; a restatement of FY2025 financials and related material weaknesses Odyssey TherapeuticsAbout $304 million combined grossLater 10-Q: 600,000 option shares sold, $265.4 million net on 16,100,000 shares Seaport Therapeutics$254.9 million gross, top of range$254,880,000 total; indications of interest from General Atlantic affiliates of up to $50 million Braveheart Bio$382.5 million gross$1.26 per share discount, $26,775,000 in total; delivery on or about August 7
The WhiteHawk row is the most instructive. Its prospectus describes a restatement concluded April 22, 2026 and the control weaknesses behind it, none of which appears in the pricing release. That is normal for a release, but IR teams should know that readers will find the difference. The mechanics of a restatement filing are covered in Virgo's guide to restatement announcements.
What patterns appear across the five IPO pricing releases?
-
Headline: all five announce the pricing of an upsized initial public offering.
-
Upsize detail: two stated the original size, INNIO and WhiteHawk. The other three said upsized without giving it.
-
Proceeds: three stated gross proceeds: Odyssey, Seaport and Braveheart. INNIO, which gets no proceeds, and WhiteHawk did not.
-
Ticker placement: Seaport and Braveheart put the ticker in the opening sentence. The other three gave it only in the trading sentence.
-
Option: all five stated the underwriters' option for additional shares.
-
Forward-looking language: INNIO, Odyssey, Seaport and Braveheart included forward-looking statements, mostly about closing. WhiteHawk used a no-assurance sentence instead.
We did not verify the original price ranges for these deals, so this page makes no claim about where each priced against its range, apart from Seaport's own wording.
What should an IR team check before issuing an IPO pricing press release?
-
Match every share count, price and date to the final prospectus before release.
-
Decide whether to state original and upsized size, and keep the numbers consistent everywhere.
-
State whether shares are primary or secondary, and say plainly who receives the proceeds.
-
Choose how to present gross proceeds, and say whether the option is included or excluded.
-
Give the exchange, ticker, first trading day and expected closing date in one place.
-
Name the lead managers exactly as the underwriting agreement does.
-
Check the registration statement effectiveness line and the prospectus request details.
-
Review forward-looking language with counsel, particularly around closing conditions.
-
Confirm the release does not contradict anything in the prospectus, and remind spokespeople of the guidance in the CEO communications during an IPO guide.
For wider investor communications, see the investor relations hub.
Frequently asked questions
What is an IPO pricing press release?
It is the announcement a company issues when its initial public offering prices. It states the number of shares, the price, the listing details and the expected closing.
What does an IPO pricing release usually include?
Typically the share count and price, the exchange and ticker, the lead managers, the underwriters' option, the prospectus request details and forward-looking language.
Must a pricing release state gross proceeds?
In these five, three did and two did not. Whether to include them is a drafting decision to make with counsel.
What does upsized mean in a pricing release?
It means the offering priced larger than first proposed. INNIO moved from 75,000,000 to 90,000,000 shares, and WhiteHawk from 6,925,000 to 7,700,000.
Where can I verify a pricing release?
Compare the release on the company's investor site or wire page with the final prospectus filed on SEC EDGAR as a 424B4.
Should the release repeat the prospectus?
No, but it should never conflict with it. Keep the figures identical and let the prospectus carry the detail.
Editorial disclosure and research notes
Sourcing. The INNIO, WhiteHawk and Seaport releases were read on company-hosted pages, and the Odyssey and Braveheart releases on GlobeNewswire. We read 424B4 cover information for INNIO, WhiteHawk, Seaport and Braveheart. Odyssey's 424B4 is on EDGAR but its cover was not read, so Odyssey's later figures come from its 10-Q. We did not verify the original price ranges, and the Braveheart 424B4 link uses the file name the SEC index shows.
Editorial judgment. The patterns, takeaways and checklist are Virgo's own judgment, not statements from the companies. Virgo PR publishes this page and provides communications services, so read the judgments as one agency's view. Offering terms are reported only as stated in the releases and filings, and no other stock price or return claims are made.
Not legal advice. This page is general information and is not legal advice. Disclosure decisions should be made with securities counsel.
Follow us
LinkedIn





